TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($3.21) per share for the quarter.
TransCode Therapeutics Stock Performance
TransCode Therapeutics stock opened at $0.49 on Monday. TransCode Therapeutics has a 52-week low of $0.49 and a 52-week high of $66.33. The firm has a 50 day moving average price of $5.01 and a two-hundred day moving average price of $216.88.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of TransCode Therapeutics in a report on Thursday, March 13th.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- Best Stocks Under $5.00
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 03/24 – 03/28
- How to Plot Fibonacci Price Inflection Levels
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
